Introgen Therapeutics Report issue

For profit Phase 2 Phase 3
Founded: Austin TX United States (1993)
Status: Defunct (2010)

Organization Overview

First Clinical Trial
2002
NCT00044993
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2006

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

ingn 201 (3 trials)

Drugs in Phase 2 Trials (2)

ingn 241 (1 trial)

recombinant adenoviral human p53 gene (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Carcinoma, Squamous Cell (Phase 3)

Melanoma (Phase 2)

Neoplasm Metastasis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 3